Articles

The results of a major study released: The Dream Study (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) with over 5000 patients Rosiglitazone reduced the risk of developing type 2 diabetes by 62 percent (p

The Dream Study also found that the ACE-inhibitor Altace (ramipril) does not prevent type 2 diabetes in patients with impaired glucose metabolism.

With less side effects then in the Dream Study and a much lower cost, study shows weight loss is the key factor in reducing diabetes risk for high-risk, overweight individuals.

People who develop type 2 diabetes when they’re younger than 50 years of age are more likely to experience a worsening of their disease than those diagnosed at an older age.

Diabetes experts have warned that urgent action needs to be taken to drastically improve the management of diabetes to prevent a potentially devastating and costly global burden. This comes from the OPTIMIZE Survey where 1500 people with type 2 diabetes were questioned about their attitudes to diabetes management.

An inhaled insulin being developed by MannKind Corp produces comparable improvements in blood sugar control to rapid-acting insulin analog (RAA) given by injection, researchers said on Saturday.

Data emerging on the safety and efficacy of the new oral antidiabetic agents were presented this week at the European Association for the Study of Diabetes 2006 Meeting.

Galvus dropped A1c by 1.8% without weight gain.

New data presented yesterday for the first time at the 42nd annual meeting of the European Association for the Study of Diabetes (EASD) in Copenhagen demonstrated a mean reduction in A1C of 2.1% from a mean baseline A1C of 8.8% and a reduction of 2.9% for those with a mean …

Levemir improves glucose control without weight gain and hypoglycemia.